Journal of Clinical Oncology, Vol 22, No 16 (August 15), 2004: pp. 3255-3260
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.11.109
Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection
Robert J. Downey,
Timothy Akhurst,
Mithat Gonen,
Alain Vincent,
Manjit S. Bains,
Steven Larson,
Valerie Rusch
From the Thoracic Surgery Service, the Division of Nuclear Medicine, and the Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY
Address reprint requests to Robert J. Downey, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: downeyr{at}mskcc.org
PURPOSE: A retrospective review of surgically treated lung cancer patients imaged preoperatively by F-18 fluorodeoxyglucosepositron emission tomography ([18F]FDG-PET) to determine if the primary tumor standardized uptake value (SUV) predicts survival.
PATIENTS AND METHODS: Nonsmall-cell lung cancer or carcinoid pT14, N02, M0 patients treated by R0 surgical resection alone were imaged with computed tomography scan and PET within 90 days before surgery. Prognostic variables were assessed by log-rank test; survival was assessed by the method of Kaplan and Meier.
RESULTS: One hundred consecutive patients (48 men, 52 women) were retrospectively reviewed. Median follow-up for surviving patients was 28 months (range, 16 to 81 months). Median maximal SUV (SUVMAX) was 9. The 2-year survival for patients with SUVMAX more than 9 was 68% and for those with SUVMAX less than 9, it was 96% (P < .01, log-rank test). In a multivariate analysis including pathologic tumor size, involved nodes, histology, and SUVMAX, only tumor size (T) more than 3 cm and SUVMAX more than 9 and their interaction were significant predictors of survival (P = .01, 0.02, and < 0.01, respectively). The 3-year survivals for patients with both T less than 3 cm and SUVMAX less than 9 was 97%; for those with T less than 3 cm and SUVMAX more than 9, it was 94%; for those with T more than 3 cm and SUVMAX less than 9, it was 93%; and for those with T more than 3 cm and SUVMAX more than 9, it was 47% (P < .01).
CONCLUSION: In surgically managed lung cancer patients, SUV is a predictor of overall survival after resection. The addition of SUVMAX to pathologic tumor size identifies a subgroup of patients at highest risk for death as a result of recurrent disease after resection.
Authors disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Garin, F. Le Jeune, A. Devillers, M. Cuggia, A.-S. de Lajarte-Thirouard, C. Bouriel, E. Boucher, and J.-L. Raoul
Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors
J. Nucl. Med.,
June 1, 2009;
50(6):
858 - 864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Hwangbo, S. K. Kim, H.-S. Lee, H. S. Lee, M. S. Kim, J. M. Lee, H.-Y. Kim, G.-K. Lee, B.-H. Nam, and J. I. Zo
Application of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Following Integrated PET/CT in Mediastinal Staging of Potentially Operable Non-small Cell Lung Cancer
Chest,
May 1, 2009;
135(5):
1280 - 1287.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Erasmus, E. Rohren, and S. G. Swisher
Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging
Proceedings of the ATS,
April 15, 2009;
6(2):
171 - 179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. R. Kim, D.-J. Kim, W. W. Lee, S. Jheon, and S. W. Sung
The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma
Eur. J. Cardiothorac. Surg.,
April 1, 2009;
35(4):
712 - 717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Sculier
Prognostic Factors and Implications of Positron Emission Tomography
ASCO Educational Book,
January 1, 2009;
2009(1):
469 - 472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Park, J. M. Goo, H. J. Lee, M. A Kim, C. H. Lee, and M.-J. Kang
Tumors in the Tracheobronchial Tree: CT and FDG PET Features1
RadioGraphics,
January 1, 2009;
29(1):
55 - 71.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Suh, Y.-K. Kang, J.-L. Roh, M. R. Kim, J. S. Kim, J. Huh, J. H. Lee, Y. J. Jang, and B.-J. Lee
Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck
J. Nucl. Med.,
November 1, 2008;
49(11):
1783 - 1789.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Al-Sarraf, K. Gately, J. Lucey, R. Aziz, K. Doddakula, L. Wilson, E. McGovern, and V. Young
Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases
Eur. J. Cardiothorac. Surg.,
October 1, 2008;
34(4):
892 - 897.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bisdas, K. Spicer, and Z. Rumboldt
Whole-Tumor Perfusion CT Parameters and Glucose Metabolism Measurements in Head and Neck Squamous Cell Carcinomas: A Pilot Study Using Combined Positron-Emission Tomography/CT Imaging
AJNR Am. J. Neuroradiol.,
August 1, 2008;
29(7):
1376 - 1381.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F.-X. Hanin, M. Lonneux, J. Cornet, P. Noirhomme, C. Coulon, J. Distexhe, and A. J. Poncelet
Prognostic value of FDG uptake in early stage non-small cell lung cancer
Eur. J. Cardiothorac. Surg.,
May 1, 2008;
33(5):
819 - 823.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Hoang, L. F. Hoagland, R. E. Coleman, A. D. Coan, J. E. Herndon II, and E. F. Patz Jr
Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non-Small-Cell Lung Carcinoma
J. Clin. Oncol.,
March 20, 2008;
26(9):
1459 - 1464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen, C. Dromain, J. Lumbroso, E. Baudin, and M. Schlumberger
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times
Eur. J. Endocrinol.,
February 1, 2008;
158(2):
239 - 246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami, N. Ny Tovo, J. Lumbroso, N. Lassau, G. Bonniaud, et al.
Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels
J. Clin. Endocrinol. Metab.,
November 1, 2007;
92(11):
4185 - 4190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Lee, J. L. Port, R. J. Korst, Y. Liss, D. N. Meherally, and N. K. Altorki
Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
Ann. Thorac. Surg.,
July 1, 2007;
84(1):
177 - 181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bryant and R. J. Cerfolio
Differences in Epidemiology, Histology, and Survival Between Cigarette Smokers and Never-Smokers Who Develop Non-small Cell Lung Cancer
Chest,
July 1, 2007;
132(1):
185 - 192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Downey, T. Akhurst, M. Gonen, B. Park, and V. Rusch
Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer
J. Thorac. Cardiovasc. Surg.,
June 1, 2007;
133(6):
1419 - 1427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Weber, J. Czernin, and M. E. Phelps
Prognostic Significance of Fluorodeoxyglucose Uptake in Non-Small Cell Lung Cancer. A Blurry Picture?
Clin. Cancer Res.,
June 1, 2007;
13(11):
3105 - 3106.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Vesselle, J. D. Freeman, L. Wiens, J. Stern, H. Q. Nguyen, S. E. Hawes, P. Bastian, A. Salskov, E. Vallieres, and D. E. Wood
Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role
Clin. Cancer Res.,
June 1, 2007;
13(11):
3255 - 3263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Cerfolio and A. S. Bryant
Ratio of the Maximum Standardized Uptake Value on FDG-PET of the Mediastinal (N2) Lymph Nodes to the Primary Tumor May Be a Universal Predictor of Nodal Malignancy in Patients With Nonsmall-Cell Lung Cancer
Ann. Thorac. Surg.,
May 1, 2007;
83(5):
1826 - 1830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Riedl, T. Akhurst, S. Larson, S. F. Stanziale, S. Tuorto, A. Bhargava, H. Hricak, D. Klimstra, and Y. Fong
18F-FDG PET Scanning Correlates with Tissue Markers of Poor Prognosis and Predicts Mortality for Patients After Liver Resection for Colorectal Metastases
J. Nucl. Med.,
May 1, 2007;
48(5):
771 - 775.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Bryant, S. J. Pereira, D. L. Miller, and R. J. Cerfolio
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non-Small Cell Lung Cancer
Ann. Thorac. Surg.,
November 1, 2006;
82(5):
1808 - 1814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Raz, A. Y. Odisho, B. L. Franc, and D. M. Jablons
Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
J. Thorac. Cardiovasc. Surg.,
November 1, 2006;
132(5):
1189 - 1195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen
FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma
Ann. Onc.,
November 1, 2006;
17(11):
1650 - 1655.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Bryant, R. J. Cerfolio, K. M. Klemm, and B. Ojha
Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non-Small Cell Lung Cancer
Ann. Thorac. Surg.,
August 1, 2006;
82(2):
417 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Pryma, H. Schoder, M. Gonen, R. J. Robbins, S. M. Larson, and H. W.D. Yeung
Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients
J. Nucl. Med.,
August 1, 2006;
47(8):
1260 - 1266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Larson and L. H. Schwartz
18F-FDG PET as a Candidate for "Qualified Biomarker": Functional Assessment of Treatment Response in Oncology
J. Nucl. Med.,
June 1, 2006;
47(6):
901 - 903.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard
Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer
J. Nucl. Med.,
April 1, 2006;
47(4):
559 - 565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Bunyaviroch and R. E. Coleman
PET Evaluation of Lung Cancer
J. Nucl. Med.,
March 1, 2006;
47(3):
451 - 469.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Leboulleux, C. Dromain, G. Bonniaud, A. Auperin, B. Caillou, J. Lumbroso, R. Sigal, E. Baudin, and M. Schlumberger
Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography
J. Clin. Endocrinol. Metab.,
March 1, 2006;
91(3):
920 - 925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, R. P. Golding, B. Biesma, F. J.H.M. Schramel, N. van Zandwijk, et al.
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
November 20, 2005;
23(33):
8362 - 8370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. W. Rusch
Mediastinoscopy: An Endangered Species?
J. Clin. Oncol.,
November 20, 2005;
23(33):
8283 - 8285.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pasic, H. A. Brokx, E. F. Comans, G. J. Herder, E. K. Risse, O. S. Hoekstra, P. E. Postmus, and T. G. Sutedja
Detection and Staging of Preinvasive Lesions and Occult Lung Cancer in the Central Airways with 18F-Fluorodeoxyglucose Positron Emission Tomography: A Pilot Study
Clin. Cancer Res.,
September 1, 2005;
11(17):
6186 - 6189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Cerfolio, A. S. Bryant, B. Ohja, and A. A. Bartolucci
The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival
J. Thorac. Cardiovasc. Surg.,
July 1, 2005;
130(1):
151 - 159.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Keidar, D. Militianu, E. Melamed, R. Bar-Shalom, and O. Israel
The Diabetic Foot: Initial Experience with 18F-FDG PET/CT
J. Nucl. Med.,
March 1, 2005;
46(3):
444 - 449.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|